Amity University

Total Page:16

File Type:pdf, Size:1020Kb

Amity University AMITY UNIVERSITY We nurture talent --------------------UTTAR PRADESH-------------------- (Established by Ritnand Balved Education Foundation) THIS IS TO CERTIFY THAT PROJECT REPORT ENTITLED “PROBLEM IDENTIFICATION AND RECTIFICATION IN CLAIM SETTLEMENT”, IN JOHNSON & JOHNSON, NEW DELHI IS PREPARED BY DEEPAK BEHAL OF MBA (GENERAL) 3rd SEMESTER, AMITY UNIVERSITY, LUCKNOW CAMPUS, UNDER MY SUPERVISION. PLACE: LUCKNOW FACULTY GUIDE: DATE: (DR. NIMISH GUPTA) STUDENT’S CERTIFICATE Certified that this report is prepared based on the summer internship project undertaken by me in Johnson & Johnson from 4th June 2007 to 16th July 2007, under the able guidance of Mr. Ajay Rangaraj, Regional Manager, sales (north) in partial fulfilment of the requirement for award of degree of Master in Business Administration From Amity University Uttar Pradesh. Date: _____________ Signature: __________ Signature: __________ Signature: __________ Name: _____________ Name: _____________ Name: _____________ Student Faculty Guide Director ABS ACKNOWLEDGEMENT The satisfaction and Euphoria that accompany the successful completion any task would be without the mention of people who make it possible and whose constant guidance and encouragement leads all effects with success. I would like to express my sincere and profound gratitude to my project guide Dr. Nimish gupta who has been a constant source of inspiration throughout my project. I thank him for the guidance given by him to complete my project. I would also like to thank my Industry guide Mr. Ajay Rangaraj who has been of great help to me and helping me whenever I needed help. Last but not the least I would like to thank Mr. Sabharwal (ABI), Mr Harish rathuri(ABI), Mr Kashif Husain(ABI), Mr Ramesh Jaswani(ABI), Mr Suresh Nandwani(FLM), and all the staff of Johnson & Johnson who helped me in successful completion of the project without them it would have been very difficult for me to complete the project successfully. In the end I would like to thank my parents for their support and posiivity which they have inherited in me and made me an optimistic person. Company’s Name: Johnson & Johnson Address: a-2 community centre, naraina industrial area phase II, New Delhi-110028 Industry Guide Name: Mr. Ajay Designation: Regional Sales Manager Rangaraj Office Phone:011- Mobile:+919311099801 Res Phone 45035242 Email ID: [email protected] Duration Weeks: 08 Start Date:04-06-07 End Date: 04-08-07 Project Title: Study the claim settlement procedure and implement a rapid claim settlement process. Project Objective: Study the market of North india and learn the bottlenecks at RDS point, ABI level and FLM level. Also formulate an error free system to overcome these problems. Methodology to be adopted: Take a sample of 2 ABI H.Q, RDS in metropolitan market and also 2 ABI H.Q, RDs in upcountry and study the problems faced in filing of claim. Brief Summary of the Project: Johnson & Johnson has 314 distributors in North India which are being taken care by 20 A.B.I (Area Business Incharge) and further they have 4 F.L.M (Front line Managers). The company launches various invoicing and retailer schemes for promotion of sales and hence the RDs file claim for the retailer schemes which has been a complex task and till date we do not have a perfect system for the same. A problem free claim filing system is required to ensure the completion of claim filing within the specified time period and also free of any errors. Johnson & Johnson has 314 distributors in North India which are being taken care by 20 A.B.I (Area Business Incharge) and further they have 4 F.L.M (Front line Managers). The company launches new offers for the distributors in order to promote its sales and examples of such offers can be 3% scheme launched in April on savlon soap 75 gm and 125 gm. The claim filing procedure has been a complex task and till date we do not have a perfect system for the same. A problem free claim filing system is required to ensure the completion of claim filing within the specified time period and also free of any errors. CLAIM Claim is an amount asked to be reimbursed by the RDS on account of certain scheme been run by him in the market which was asked by the company to be run. Claims are not only limited to the schemes but also they are for the damages of goods. Claims can be any of the following types: Primary Claims Secondary Claims Permanent Window Display Visibility Damages Coupons Hanger Claims do not have any limitation, they can be for anything (for schemes run in the market, for any expense reimbursement, company parties etc) and every claim is different from the other. However all of have one thing in common and that is they ask for reimbursement from the company Procedure of Filing Claim DISTRIBUTOR ↓ AREA BUSINESS INCHARGE ↓ FRONT LINE MANAGER ↓ REGIONAL MANAGER As of today the claim filing procedure is very simple i.e the claims are filed by the distributor to their particular AREA BUSINESS INCHARGE and the ABI’s forward it to the FRONT LINE MANAGERS who further pass it on to the REGIONAL MANAGER. Appropriation Number Appropriation number is a specific number assigned to a particular scheme/activity for a particular period which may or may not be for a year. This number gives the appropriate amount assigned for the promotion of a particular product for a particular period which may or may not be for a year. This helps the marketing and sales department to have a control over the spending . Example of receipt of appropriation number: pl note... Regards, Sanjay -----Original Message----- From: Tiku, Ashima [JNJINBO] Sent: Friday, February 09, 2007 5:24 PM To: Machado, Reynold [JNJINBO]; Arora, Sanjay [JNJINBO]; Shettigar, Ganesh [JNJINMH]; Malini, P. [JNJINMA] Cc: Saran, Vaibhav [JNJINBO]; Dubey, Ashok [JNJINBO]; Aravind T. [JNJINBO]; Lobo, Doreen [JNJINBO] Subject: Aps nos for 2007 Importance: High Dear All, attached please find the list of APs for settling claims related to schemes on brands. The AP nos are for the schemes that would be run in the period Jan- June 2007. The brands like baby soap, powder etc include the schemes run on their variants as well. Regarding settlement of RDSSM incentives, we are awaiting the plans from the RSMs...the regional TPR APs can only be raised post that The AP nos to settle Key Account claims would be sent out shortly, post Aravind's revert Would request you to please let me know in case any clarifications are required on the above, Thanks and regds, Ashima App. No. Brand Amount (Rs. 000) TPR-276000 Band aid- Washproof 4000 TPR- 276001 Savlon Liquid 2575 TPR- 276002 Baby Soap 7450 TPR- 276003 Baby Powder 4840 TPR- 276004 Baby Oil 11000 TPR- 276005 Baby Cream 4350 TPR- 276006 Baby Lotion 1775 TPR- 276007 NMT shampoo 1575 TPR- 276008 Baby Hair Oil 775 TPR- 276009 Buds 1025 TPR- 276010 Nappy. Pads 750 TPR- 276011 Shower to Shower 4600 TPR- 276012 Clean & Clear 960 TPR- 276013 Band-Aid Regular 1420 TPR- 276014 Band-Aid Flexi 9375 TPR- 276015 Savlon Soap 4025 TPR- 276016 Capsicum Plasters 1400 TPR- 276017 Carefree Sanitary Napkins 1820 TPR- 276018 Stayfree Ultrathin Dry Max 5650 TPR- 276019 Stayfree Secure 22100 IMPORTANCE OF FILING CLAIM ON TIME Every claim carries importance and it should be submitted on time and timely receipt of claims is very important for the finance and accounts department. Also these claims tell us that how efficiently the scheme has been utilized. The appropriation number comes from the head office along with the budget allocated for that particular SKU and once the claims come we get the amount used out of that budget provided to us which is very important. So, these claims should come on time. AREAS TO WORK ON In order to make a perfect claim settlement system there are various areas which require special attention and to ensure the claim reaches the office on time and get sanctioned every month and those areas are: Distributor Area Business Incharge Front line Managers The claim submission system should not only be free of any problems but also simplified to ensure that there is less amount of hard work required for settlement and it should easily be cross checked. LIST OF PEOPLE TO MEET Area Business Incharge NAME AREA D.K.Sabharwal Delhi Harish Raturi Delhi Suresh Keswani Delhi Kashif Hussain Delhi Shalesh Pandey Uttar Pradesh Sunil Dutt Trivedi Uttar Pradesh Saurabh Awasthi Uttar Pradesh Sanjay Singh Uttar Pradesh Rajesh Babbar Uttar Pradesh R.K.Jaswani Uttar Pradesh Naveen Jain Uttar Pradesh Gaurav Sharma Uttar Pradesh A.M.Prasad Uttar Pradesh Y.P.Dhir Punjab Rajesh Gaur Punjab B.S.Lamba Punjab Anurag Srivastava Punjab Amit Pareek Rajasthan Anuj Rastogi Rajasthan Rohit Mehrotra Rajasthan Front Line Managers: NAME AREA Anil Sharma Delhi Gurmeet Singh Punjab, Haryana, Himachal Pradesh, J&K S.K.Dhar Rajasthan S.Nandwani Uttar Pradesh & Uttaranchal At Johnson & Johnson there is no mission statement that hangs on the wall. Instead, for more than 60 years, a simple, one-page document – Our Credo – has guided our actions in fulfilling our responsibilities to our customers, our employees, the community and our stockholders. Our worldwide Family of Companies shares this value system in 36 languages spreading across Africa, Asia/Pacific, Eastern Europe, Europe, Latin America, Middle East and North America. Johnson & Johnson’s Credo We believe our first responsibility is to the doctors, nurses and patients, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to reduce our costs in order to maintain reasonable prices.
Recommended publications
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • Approved Prenatal Medications Pain Medications • Tylenol
    Approved Prenatal Medications Pain Medications Tylenol (acetaminophen) for minor aches and pains, headaches. (Do not use: Aspirin, Motrin, Advil, Aleve, Ibuprofen.) Coughs/Colds Robitussin (Cough) Robitussin DM (non-productive cough) DO NOT USE TILL OVER 12 WEEKS Secrets and Vicks Throat Lozenges Mucinex Sore Throat Chloraseptic spray Saline Gargle Sucrets and Vicks Throat Lozenges Antihistamines/Allergies Zyrtec Claritin Benadryl Dimetapp Insomnia Benadryl Unison Hemorrhoids Preparation H Tucks Anusol Diarrhea Imodium (1-2 doses- if it persists please notify the office) BRAT diet (bananas, rice, applesauce, toast) Lice RID (only!) DO NOT USE Kwell Itching Benadryl Calamine or Caladryl Lotion Hydrocortisone cream Heartburn, Indigestion, Gas Tums Gas-X Mylanta Pepcid Maalox Zantac *DO NOT USE PEPTO BISMOL- it contains aspirin Decongestants Sudafed Robitussin CF- Only if over 12 weeks Tavist D Ocean Mist Nasal Spray (saline solutions) Nausea Small Frequent Meals Ginger Ale Vitamin B6 Sea Bands Yeast Infections Monistat Mycolog Gyne-lotrimin Toothache Orajel May see dentists, have cavity filled using Novocain or lidocaine, have x-rays with double lead shield, may have antibiotics in the Penicillin family (penicillin, amoxicillin) Sweetners- all should be consumed in moderation with water being consumed more frequently Nutrisweet (aspartame) Equal (aspartame) Splenda (sucralose) Sweet’n Low (saccharin) *note avoid aspartame if you have phenylketonuria (PKU) Constipation Colace Fibercon Citrucel Senokot Metamucil Milk of Magnesia Fiberall Miralax Eczema Hydrocortisone Cream Medications to AVOID Accurate Lithium Paxil Ciprofloxacin Tetracycline Coumadin Other Chemicals to AVOID Cigarettes Alcohol Recreational Drugs: marijuana, cocaine, ecstasy, heroin .
    [Show full text]
  • Diabetes Close up December Supplement, 2005, No. 53 J&J To
    Diabetes Close Up December supplement, 2005, No. 53 J&J To Buy Animas in Sublime Strategic Play T h e S h o r t e r V e r s i o n From the Editor: J&J’s LifeScan announced December 16 that it intends to buy Animas Corporation for $518 million in cash, or $24.50/share, a 35% premium over Animas’ closing price the 15th. We think this acquisition makes very good strategic sense – essentially, it’s the #1 glucose monitoring company buying the #2 pump player. In many respects, this was a classic J&J deal – Animas is newly profitable this year, the deal is immediately accretive, and it offers J&J an excellent leg up as it enters the pump market. Too, J&J had owned ~10% of Animas for some time. Now, while Animas is #2, it is still far behind leader Medtronic MiniMed, whose new(ish) leader, successful cardiac surgery veteran Bob Guezuraga has really impressed the diabetes community. Smart, ambitious, and seemingly hyper-focused, he appears very serious about taking the business to the next level and leaving success in diabetes as his legacy. What could be better for patients than significant focus industry-wide on better physiologic delivery? As competition heightens, we expect innovation to move faster – all good, from a patient perspective. Details on the acquisition are below – what J&J gets, what Animas gets, and what’s next. What a way to end what’s been a very dynamic year in diabetes … --Kelly L. Close DCU #53, December supplement 2005, J&J Buys Animas in Sublimely Strategic Deal.
    [Show full text]
  • Creative Director 561.714.1585 Andy Mathurin
    Hello, I am: Looking for role as: Let’s Connect: Andy Mathurin Creative Director 561.714.1585 Associate Creative Director, [email protected] Brand Strategist New York What I do: PROFILE Brand Strategy Over 8 years leading branding and marketing concepts with career spanning 360 campaigns, broadcast, print, OOH, social, digital, video and experiential Identity Design across major worldwide brands. Energetic and a creative visionary offering Storytelling demonstrated expertise in all aspects of branding and strategy, with core focus Thought Leader on delivering business results. Team Builder Marketing WINS Project Management Successes have included winning several accounts for new business, resulting in agency being awarded Global Agency of the Year by AdAge & Adweek. Toolkit: AOR: Havas - Vascepa 2019, Havas - Alcon 2019, J3 - OGX 2018, UM - H&M 2017, UM - Sony 2017, BMW 2016, UM - Coca Cola 2016 Sketch XD Microsoft Office PROFESSIONAL EXPERIENCE Avocode 03.18 HAVAS | Manhattan, NY Photoshop Present Associate Creative Director Strategic partner, focusing on brand equity for healthcare and InDesign pharmaceutical brands. Responsible for new business and leading creative Illustration team/studio across all digital platforms (specializing in social). After Effects Brands include: Zicam, Alcon, GSK, NUCALA, TRELEGY, & ANORO. 09.14 Universal McCann Worldwide | Manhattan, NY 03.18 Personality: Associate Creative Director + Senior Art Director Hands-on leader in identity design. Champion participant in winning new Human business pitches. Guiding and advising clients on high-level executions. Confident Brands include: Sony Pictures, GoPro, McCormick, BMW... and more. Effective Communicator - Demonstrate strong leadership overseeing staff in the day-to-day projects Motivational Honest with Integrity - Deliver against demanding brand objectives and develop creative that Empathetic exceeds business needs, managing projects from concept through completion: timelines, budgets, schedules, etc.
    [Show full text]
  • Bowling V. Johnson & Johnson, Et
    Case 1:17-cv-03982-AJN Document 1 Filed 05/25/17 Page 1 of 21 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK SUZANNA BOWLING, individually and on behalf of all others similarly situated, CASE NO. Plaintiff, v. CLASS ACTION COMPLAINT JOHNSON & JOHNSON and McNEIL NUTRITIONALS, LLC, JURY TRIAL DEMANDED Defendants. Plaintiff Suzanna Bowling brings this action on behalf of herself and all others similarly situated against Defendants Johnson & Johnson and McNeil Nutritionals, LLC (“McNeil”) (collectively, “J&J” or “Defendants”). Plaintiff makes the following allegations pursuant to the investigation of her counsel and based upon information and belief, except as to the allegations specifically pertaining to herself, which are based on personal knowledge. NATURE OF THE ACTION 1. This is a class action lawsuit regarding Defendants’ false and misleading labeling of Benecol Regular and Light Spreads (together, “Benecol Spreads”), each of which uniformly claims that the product (i) contains “No Trans Fats” and “No Trans Fatty Acids,” and (ii) is generally recognized as safe for human consumption (the “Misrepresentations”). However, Benecol Spreads contain trans fat through the use of partially hydrogenated oils. Thus, the labels on Benecol Spreads are false and misleading. Case 1:17-cv-03982-AJN Document 1 Filed 05/25/17 Page 2 of 21 2. In June 2015, the FDA concluded that partially hydrogenated oils – the same oils found in Benecol Spreads – are not “generally recognized as safe” for use in human food due to “an increased risk of coronary heart disease by contributing to the buildup of plaque inside the arteries that may cause a heart attack.” Thus, Benecol Spreads are not generally recognized as safe for human consumption.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • Open PDF File, 175.47 KB, for Top 100 Covered Recipients, Non Hospital
    Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events QUADRANT HEALTH BEVERLY MA Clinical 22D2063293 357395 Novartis CC0243 Other 61 $2,251,831.00 STRATEGIES INC Laboratory Pharmaceuticals 1 Total for Covered Recipient : QUADRANT HEALTH STRATEGIES INC $2,251,831.00 BOSTON BOSTON MA Clinical 22D0996308 241308 Celgene CC0109 Grants/ 2 $30,000.00 UNIVERSITY Laboratory Corporation Educational SCHOOL OF Gifts MEDICINE Csl Behring Llc CC0101 Education/ 2 $5,000.00 Training Depuy CC0135 CMEs, third- 2 $26,000.00 Orthopaedics, Inc., party Conferences, or Meetings Other 1 $7,500.00 Dr. Reddy's CC0592 Grants/ 2 $121,820.00 Laboratories, Inc Educational Gifts Janssen Biotech, CC0194 Grants/ 2 $105,000.00 Inc. Educational Gifts Other 1 $1,500.00 Janssen CC0535 CMEs, third- 2 $175,000.00 Pharmaceuticals, party Inc. Conferences, or Meetings Novo Nordisk Inc. CC0006 Grants/ 2 $136,436.00 Educational Gifts Smith & Nephew, CC0402 CMEs, third- 1 $1,000.00 Inc. party Conferences, or Meetings Stryker Corporation CC0290 CMEs, third- 1 $1,000.00 party Conferences, or Meetings Takeda CC0300 CMEs, third- 2 $60,218.00 Pharmaceuticals party Aug 1, 2016 1 8:44:29 AM Top 100 Covered Recipients, Non Hospital, Detail Rank Recipient City State License License Covered Manufacturer Manufacturer Payment Number Total Fullname Type Number Recipient Name ID Categories of Payment ID Events BOSTON BOSTON MA Clinical 22D0996308 241308 America, Inc CC0300 Conferences, or UNIVERSITY Laboratory Meetings SCHOOL OF Grants/ 3 $800,000.00 MEDICINE Educational Gifts Valeant CC0346 CMEs, third- 2 $5,000.00 Pharmaceuticals party North America Conferences, or Meetings W.L.
    [Show full text]
  • Ronald Monk, Et Al. V. Johnson & Johnson, Et Al. 10-CV-04841
    James E. Cecchi D. Seamus Kaskela Lindsey H. Taylor David M. Promisloff CARELLA, BYRNE, CECCHI, BARROWAY TOPAZ KESSLER OLSTEIN, BRODY & AGNELLO, P.C. MELTZER & CHECK, LLP 5 Becker Farm Road 280 King of Prussia Road Roseland, New Jersey 07068 Radnor, Pennsylvania 19087 (973) 994-1700 (610) 667-7706 Ramzi Abadou Erik D. Peterson Stacey Kaplan BARROWAY TOPAZ KESSLER MELTZER & CHECK, LLP 580 California Street, Suite 1750 San Francisco, California 94104 (415) 400-3000 Attorneys for Plaintiff UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY Civil Action No. RONALD MONK, Individually and on Behalf of All Others Similarly Situated, Plaintiff, vs. COMPLAINT and DEMAND FOR JURY TRIAL JOHNSON & JOHNSON, WILLIAM C. WELDON, DOMINIC J. CARUSO and PETER LUTHER, Defendants. Plaintiff Ronald Monk, individually and on behalf of others similarly situated, by way of Complaint against Johnson & Johnson, William C. Weldon, Dominic J. Caruso, and Peter Luther, say: INTRODUCTION AND OVERVIEW 1. This is a class action for violations of the anti-fraud provisions of the federal securities laws on behalf of all purchasers of Johnson & Johnson (“JNJ” or the “Company”) publicly traded securities between October 14, 2008 and July 21, 2010 (the “Class Period”), who were damaged thereby. 2. JNJ is a healthcare company that sells, among other things, over-the-counter (“OTC”) drugs to consumers. During the Class Period, defendants repeatedly touted the success and revenue of OTC drug sales by its subsidiary McNeil-PPC, Inc. (“McNeil”). At the same time, defendants failed to disclose that a number of manufacturing facilities were failing to maintain current good manufacturing practices (“cGMPs”).
    [Show full text]
  • Palm Oil Shopping Guide: Current Best Choices
    FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of Make a Difference RSPO Members RSPO Members RSPO Members RSPO Members RSPO Members for Wild 3 Musketeers Cinnamon Toast Crunch Honey Maid Grahams Mothers Cookies Splenda Orangutans Act II Coffee Mate Hot Pockets Mountain High Yogurt Starburst Adam's PB Country Crock Hungry Jack Muffin Mam Pastries Stouffers Almond Joy Country Time Hunt's Muir Glen Trident Gum BOYCOTTING PALM Altoids Crisco International Delight Nabisco Sun Chips OIL IS NOT THE Arnott's Biscuits Crunch and Munch Jenny Craig Meals Nature Valley SuperMoist Cake Mixes SOLUTION… Aunt Jemima Foods Dean's Dips Jeno's Pizza Near East Sweet Rewards Bars Austin Brand Crackers Doritos Jif PB Nerds Sweet Tarts Supporting Baby Ruth Dove Chocolates Jiffy Pop Nesquik Swiss Miss companies that are Bac Os Dreyer's Jolly Ranchers Nestle Products Tombstone Pizza members of the Baker's Chocolate Edy's Justin's NutButter Nutter Butter Cookies Tostitos RSPO (Roundtable on Balance Bars Egg Beaters Justin's PB Cups Old El Paso Total Cereal Sustainable Palm Oil) Banquet Meals Endangered Species Choc. Keebler Cookies Oreo Cookies Totino's Pizza is the most Barilla Famous Amos Cookies Keebler Crackers Orville Redenbacher's Trix Cereal responsible solution. BelVita Fiber One Products Kellogg's Products Pam Tuna Helper Ben & Jerry's Ice Cream Fleischmann's Kid Cuisine Parent's Choice Twix Bertolli Frito Lay Kit Kat Parkay Twizzlers For more information Betty Crocker products Folgers Kix Cereal Pasta
    [Show full text]
  • Medtronics / Animas
    Completed acquisition by Medtronic plc of certain assets of Animas Corporation Decision on relevant merger situation and substantial lessening of competition Please note that [] indicates figures or text which have been deleted or replaced in ranges at the request of the parties for reasons of commercial confidentiality. SUMMARY 1. On 19 December 2017 Medtronic plc (Medtronic) acquired certain assets (the Target Assets) from Animas Corporation (Animas), a subsidiary of Johnson & Johnson (J&J) (the Merger). Medtronic and the Target Assets are together referred to as the Parties. 2. The Competition and Markets Authority (CMA) notes that the Merger does not involve an extensive transfer of assets. For example, it does not provide for the transfer of any physical assets (eg insulin pumps or consumables), fixed assets (eg manufacturing facilities), intellectual property, R&D assets and information, or employees. 3. The CMA notes, however, that the customer and patient records being transferred through the Merger appear to be of significant value and that the combination of these assets with the other transferred assets appears to support a degree of ‘economic continuity’ that may enable Medtronic to carry on the business previously supported by these assets. 4. The CMA therefore believes that the Target Assets may be an enterprise, and that as a result of the Merger, the enterprises of Medtronic and the Target Assets have ceased to be distinct. 5. The share of supply test is met. The four-month period for a decision, as extended, has not yet expired. The CMA therefore believes that it is or may be the case that a relevant merger situation has been created.
    [Show full text]
  • 2016 Annual Report
    ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs.
    [Show full text]
  • 2012 Annual Report (Essentials)
    Please visit jdrf.org/2012annualreport to view the entire Annual Report online. 2012 Annual Report (Essentials) 42 YEARS. 42 REASONS. Please visit jdrf.org/2012annualreport to view the entire Annual Report online. Table of Contents CEO Message ...........................................................3 JDRF Supporters ....................................................5 Financials ................................................................24 Leadership ..............................................................25 About JDRF JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Type 1 diabetes is an autoimmune disease that strikes both children and adults. Unrelated to diet or lifestyle, T1D causes lifelong dependence on injected or pumped insulin and carries the constant danger of life-threatening complications. It requires intensive, 24/7 management. There are no days off, and there is no cure. Parents founded JDRF in 1970 to help their children with T1D by funding research to find a cure for this poorly understood and often deadly disease. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF has grown to become the largest nongovernmental funder of T1D research. JDRF has awarded more than $1.7 billion to diabetes research since our founding. Our goal is simple: we want to create a world without T1D. JDRF is the only global organization with a strategic plan to bring a continuous stream of life-changing therapies, and ultimately, a cure for T1D. 2 Please visit jdrf.org/2012annualreport to view the entire Annual Report online. CEO Message A Vision for the Future Our 2012 Annual Report is a JDRF isn’t just imagining keeping patients healthy celebration of JDRF’s 42nd this future. We’re making it and safe until our vision is year highlighting many of happen.
    [Show full text]